Recent 8-K filings for CCEL
Highest-materiality recent filing
Duke terminates patent license with Cryo-Cell effective May 17; Cryo-Cell previously sought arbitration
- Duke University terminated Patent and Technology License Agreement effective May 17, 2025, claiming Cryo-Cell breached.
- Cryo-Cell had previously filed a demand for arbitration against Duke, alleging fraudulent inducement and breach.
-
NYSE American accepts Cryo-Cell compliance plan; trading continues through Sep 2027
Received notice of non-compliance on Mar 12, 2026 for stockholders' deficit and net losses in two of three fiscal years ending Nov 30, 2025.
-
Cryo-Cell receives NYSE American delisting notice over stockholders' deficit and net losses
NYSE American cited stockholders' deficit as of Nov 30, 2025 and net losses in two of three fiscal years ended Nov 30, 2025.
-
Cryo-Cell International suspends Q4 2025 dividend; future payouts uncertain
Company will not declare a quarterly cash dividend for Q4 fiscal 2025.
-
Duke University terminated Patent and Technology License Agreement effective May 17, 2025, claiming Cryo-Cell breached.
-
Cryo-Cell reduces quarterly dividend to $0.15 per share, payable May 30, 2025
Board declares reduced quarterly cash dividend of $0.15 per share, citing current economic environment and capital allocation alternatives.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.55 · Most common event dividend